Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Proactive news headlines: finnCap, EQTEC, Union Jack & Reabold and more

Altech Chemicals Ltd (ASX:ATC)’s recent site visit to its Silumina Anodes™ pilot plant in Saxony, Germany, has led to a final construction contract with Küttner GmbH & Co. KG.

Küttner is a German engineering firm with strong experience in delivering metallurgical plant projects and has worked with Altech to complete final plant engineering design and cost estimation. It has strong experience in design, procurement, project and construction management and plant commissioning across a range of industries.

Read more

Bradda Head Lithium Ltd said it has received conditional permission to begin a drilling programme at its San Domingo pegmatite district in Arizona, US.

The AIM-traded company has permission for an initial 30-hole drilling programme, pending a bond payment adjudication. Drilling is expected to start as soon as the bond payment has been received, usually in no more than 30 days, it said.

Read more

Gaming Realms PLC (AIM:GMR, OTCQX:PSDMF) has been awarded an Online Gaming Service Provider licence by Connecticut's Department of Consumer Protection.

The developer and licensor of mobile-focused gaming content is now licensed in four US states.

Read more

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF), which is developing a new class of synthetic anti-infectives, welcomes the news that its candidate RECCE® 327 (R327) returned a good safety and tolerability profile among 10 healthy male subjects.

The Phase 1 intravenous clinical trial’s sixth cohort was dosed at 4,000 milligrams – an 80-fold increase on the first cohort’s 50-milligram dose.

Read more

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK